Biology subjects

Bond, S. T.

Publications and source records attributed to Bond, S. T..

6 recordsLinked to original sources

bioRxiv2026

An Injectable Antisense Oligonucleotide (ASO) Approach to Treat Obesity in Preclinical Models

Obesity leads to metabolic dysregulation and thus drives complications including type 2 diabetes, cardiovascular disease, steatotic liver disease and some cancers. Obesity is primarily driven by lifestyle factors, which impacts individuals differently depending on their genetic susceptibility. Studies on this genetic risk have provided major insights into gene networks that modulate obesity development, including incretins and their regulatory circuits. Indeed, incretin-based therapeutics (i.e. GLP1 RA) have proven to be enormously successful in promoting weight loss, but do so with several ongoing challenges including significant weight rebound upon cessation, loss of lean mass, and side effects that reduce therapeutic longevity. Thus, ongoing research is necessary to identify additional interventions that overcome or minimise these concerns. To this end, in our previous work we have identified a novel lipid regulatory protein with potential to influence lipid storage. In the current study, we use antisense oligonucleotides (ASO) to silence this protein in mouse models of diet induced obesity, and demonstrate that once weekly IP injections of ASO prevents the development of obesity, and defends against the progression of existing obesity. This is shown to be effective in multiple mouse strains fed different diets over various time frames, with gene targeting ASOs leading to reductions in fat mass, no change in lean mass, along with improvements in whole body glucose tolerance and steatotic liver disease. Additional studies demonstrate that this phenotype is likely driven by effects in adipose tissue, but not liver, and is not linked to activation of the Type 1 Interferon response, a previously implicated off target effect of ASO administration. Thus, these studies demonstrate that our injectable ASO approach in mice can successfully treat obesity in the absence of major change in lean mass, thus positioning this intervention as a therapeutic program that works alternatively to, or in conjunction with current weight loss medicines.

physiology↗

bioRxiv2026

Inducible Impairment of Polymerase Gamma Activity in Cardiomyocytes Promotes Severe Cardiomyopathy with Cardiac Hepatopathy

Mitochondrial dysfunction is a hallmark feature of heart failure (HF) and cardiomyopathy, with substantial human and preclinical evidence suggesting that congenital mitochondrial defects can directly drive these conditions. Despite these strong links, not all individuals with mitochondrial disease develop cardiomyopathy, and therefore the precise mitochondrial defects that initiate cardiac pathology in this setting remain incompletely understood. Here, we describe a novel mouse model that induces progressive deterioration in mtDNA integrity specifically in cardiomyocytes. This model was generated through a post developmental, cardiomyocyte specific deletion of the exonuclease domain of Polymerase Gamma (PolG), impairing its ability to repair mtDNA. Strikingly, from just 16 weeks post-induction these mice displayed progressive worsening of cardiac output, ejection fraction, global strain and blood pressure culminating in premature death at 28-30 weeks post-mutation. Morphologically, these mice displayed cardinal features of hypertrophic cardiomyopathy with enlarged hearts, ventricles and cardiac fibrosis - but little evidence of congestive HF. We also demonstrate using various transcriptional and proteomic readouts, that signalling pathways characteristic of cardiomyopathy were activated. Interestingly, prior to substantial declines in cardiac function, we detect robust activation of the integrated stress response (ISR) in PolGMut mice, and major rewiring of mitochondrial folate metabolism pathways, suggesting that these pathways underpin the developing pathology. Lastly, we also observed a striking hepatopathy phenotype in mutant mice reminiscent of that observed in patients with HF, a condition not robustly recapitulated previously in other mouse models. Thus, our data establish a direct link between mtDNA instability leading to chronic activation of the ISR and rewiring of folate metabolism in cardiomyocytes, subsequently driving a severe cardiac phenotype associated with hepatopathy.

physiology↗

bioRxiv2024

Skeletal Muscle Specific PolG Dysfunction Activates the Integrated Stress Response and Promotes a Cachexia like Phenotype

During mitochondrial damage, information is relayed between the mitochondria and nucleus to coordinate precise responses to preserve cellular health. One such pathway is the mitochondrial integrated stress response (mtISR), which is specifically activated by mitochondrial DNA (mtDNA) damage. However, the causal molecular signals responsible for this activation remain elusive. A gene often associated with mtDNA mutations/deletions is Polg1, which encodes the mitochondrial DNA Polymerase {gamma} (PolG). Here, we describe what is to our knowledge the first conditional muscle specific model of PolG mutation, and demonstrate a rapid development of mitochondrial dysfunction and cachexia in these animals from [~]5 months of age. Detailed molecular profiling of muscles demonstrated robust activation of the mtISR, likely mediated upstream by the HRI/DELE1 stress pathway. This was accompanied by striking alterations to the mitochondrial folate cycle and its metabolites, strongly implying imbalanced folate intermediates as a previously unrecognised pathology driving the mtISR in mitochondrial disease.

physiology↗

bioRxiv2022

Amyloid beta 42 alters cardiac metabolism and impairs cardiac function in obesity

There are epidemiological associations between obesity and type 2 diabetes, cardiovascular disease and Alzheimers disease. While some common aetiological mechanisms are known, the role of amyloid beta 42 (A{beta}42) in these diverse chronic diseases is obscure. Here we show that adipose tissue releases A{beta}42, which is increased from adipose tissue of obese mice and is associated with higher plasma A{beta}42. Increasing circulating A{beta}42 levels in non-obese mice had no effect on systemic glucose homeostasis but had obesity-like effects on the heart, including reduced cardiac glucose clearance and impaired cardiac function. These effects on cardiac function were not observed when circulating levels of the closely related A{beta}40 isoform were increased. Administration of an A{beta} neutralising antibody prevented obesity-induced cardiac dysfunction and hypertrophy. Furthermore, A{beta} neutralising antibody administration in established obesity prevented further deterioration of cardiac function. Multi-contrast transcriptomic analyses revealed that A{beta}42 impacted pathways of mitochondrial metabolism and exposure of cardiomyocytes to A{beta}42 inhibited mitochondrial function. These data reveal a role for systemic A{beta}42 in the development of cardiac disease in obesity and suggest that therapeutics designed for Alzheimers disease could be effective in combating obesity-induced heart failure.

physiology↗

bioRxiv2021

SOD2 in Skeletal Muscle: New Insights from an Inducible Deletion Model

Metabolic conditions such as obesity, insulin resistance and glucose intolerance are frequently associated with impairments in skeletal muscle function and metabolism. This is often linked to dysregulation of homeostatic pathways including an increase in reactive oxygen species (ROS) and oxidative stress. One of the main sites of ROS production is the mitochondria, where the flux of substrates through the electron transport chain (ETC) can result in the generation of oxygen free radicals. Fortunately, several mechanisms exist to buffer bursts of intracellular ROS and peroxide production, including the enzymes Catalase, Glutathione Peroxidase and Superoxide Dismutase (SOD). Of the latter there are two intracellular isoforms; SOD1 which is mostly cytoplasmic, and SOD2 which is found exclusively in the mitochondria. Developmental and chronic loss of these enzymes has been linked to disease in several studies, however the temporal effects of these disturbances remain largely unexplored. Here, we induced a post-developmental (8-week old mice) deletion of SOD2 in skeletal muscle (SOD2-iMKO) and demonstrate that 16 weeks of SOD2 deletion leads to no major impairment in whole body metabolism, despite these mice displaying alterations in aspects of mitochondrial abundance and voluntary ambulatory movement. Furthermore, we demonstrated that SOD2 deletion impacts on specific aspects of muscle lipid metabolism, including the abundance of phospholipids and phosphatidic acid (PA), the latter being a key intermediate in several cellular signaling pathways. Thus, our findings suggest that post-developmental deletion of SOD2 induces a more subtle phenotype than previous embryonic models have shown, allowing us to highlight a previously unrecognized link between SOD2, mitochondrial function and bioactive lipid species including PA.

physiology↗

bioRxiv2021

Detailed metabolic phenotyping of four tissue specific Cas9 transgenic mouse lines

CRISPR/Cas9 technology has revolutionized gene editing and fast tracked our capacity to manipulate genes of interest for the benefit of both research and therapeutic applications. Whilst many advances have, and continue to be made in this area, perhaps the most utilized technology to date has been the generation of knockout cells, tissues and animals by taking advantage of Cas9 function to promote indels in precise locations in the genome. Whilst the advantages of this technology are many fold, some questions still remain regarding the effects that long term expression of foreign proteins such as Cas9, have on mammalian cell function. Several studies have proposed that chronic overexpression of Cas9, with or without its accompanying guide RNAs, may have deleterious effects on cell function and health. This is of particular concern when applying this technology in vivo, where chronic expression of Cas9 in tissues of interest may promote disease-like phenotypes and thus confound the investigation of the effects of the gene of interest. Although these concerns remain valid, no study to our knowledge has yet to demonstrate this directly. Thus, in this study we used the lox-stop-lox (LSL) spCas9 ROSA26 transgenic (Tg) mouse line to generate four tissue-specific Cas9-Tg models with expression in the heart, liver, skeletal muscle and adipose tissue. We performed comprehensive phenotyping of these mice up to 20-weeks of age and subsequently performed molecular analysis of their organs. We demonstrated that Cas9 expression in these tissues had no detrimental effect on whole body health of the animals, nor did it induce any tissue-specific effects on energy metabolism, liver health, inflammation, fibrosis, heart function or muscle mass. Thus, our data suggests that these models are suitable for studying the tissue specific effects of gene deletion using the LSL-Cas9-Tg model, and that phenotypes observed utilizing these models can be confidently interpreted as being gene specific, and not confounded by the chronic overexpression of Cas9.

molecular biology↗